HIV | Penta

17

Sep, 2020

Central and Eastern European Meeting on Viral Hepatitis and HIV

Tags: HIV

The Central and Eastern European Meeting on Viral Hepatitis and HIV is an independent program, initiated in 2014 and developed by regional and international key opinion leaders for the medical and scientific community in Eastern and Central European countries. The target audience of this meeting consists of healthcare professionals involved in daily care for HCV patients such as infectious disease doctors, gastroenterologists, hepatologists and others. The sixth edition of the Central and Eastern European Meeting on Viral Hepatitis and HIV will be held as a virtual conference. To apply for virtual participation scholarships click here. Click here for […]

9

Sep, 2020

Actual problems of HIV Infection: Mother and Child

Tags: HIV, AIDS

Penta has been invited to run a one-day session at the Republican Hospital of Infectious Diseases, St Petersburg conference on ‘Actual problems of HIV Infection: Mother and Child’ on Tuesday 15th September. The Penta session What’s new for children and women living with HIV: interactive clinical day with Penta will look at new data on ART in pregnancy and newborns, resistance and recommendations for 1st, 2nd and further lines, supporting our adolescents and coinfections. Register to conference!

7

Sep, 2020

The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus

Tags: HIV

Authors: Bollen P, Freriksen J, Konopnicki D, Weizsäcker K , et al; on behalf of the Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women Network Published in: Clin infect Dis. 2020;26.ciaa006 Background Pharmacokinetic and efficacy data on dolutegravir in pregnant women living with human immunodeficiency virus (HIV) are still limited but needed to support its use as one of the preferred antiretroviral agents. Methods Within the multicenter Pharmacokinetics of ANtiretroviral agents in HIV-infected pregNAnt women (PANNA) study, pregnant women living with HIV and using dolutegravir once daily (50 mg, with food) […]

13

Aug, 2020

A reason to SMILE – we reached Last Patient Last Visit

Tags: HIV, Clinical trials, AIDS

Last Patient Last Visit (LPLV) completed for the Penta 17 Strategy for Maintenance of HIV suppression with integrase inhibitor + darunavir/ritonavir in children (SMILE) trial.

6

Aug, 2020

ODYSSEY trial data published in Lancet – shows increase in treatment options for older children living with HIV

Tags: HIV

Results from from the ongoing P1093 and ODYSSEY (PENTA20) studies, published in The Lancet HIV journal, show that children over 20kg in weight can safely take adult doses (50mg) of the anti-HIV drug dolutegravir.

21

Jul, 2020

The CARMA study: early infant antiretroviral therapy—Timing impacts on total HIV-1 DNA quantitation 12 years later

Tags: EPIICAL, HIV

Authors: Foster C, Domínguez-Rodríguez S, Tagarro A, et al. For the Early Treated Perinatally HIV Infected Individuals: Improving Children’s Actual Life (EPIICAL) Consortium Published in: J Pediatr Infect Dis Soc. 2020 2020 Jul 17;piaa071 Background Strategies aimed at antiretroviral therapy (ART)–free remission will target individuals with a limited viral reser- voir. We investigated factors associated with low reservoir measured as total human immunodeficiency virus type 1 (HIV-1) DNA in peripheral blood mononuclear cells (PBMCs) in perinatal infection (PaHIV). Methods Children from 7 European centers in the Early Treated Perinatally HIV […]

13

Jul, 2020

EPPICC focus on COVID-19 impact on children and adolescents living with HIV

Tags: HIV, COVID-19, COVID19

EPPICC was awarded a grant from the ViiV Global HIV and COVID-19 Emergency Fund to conduct research on the direct and indirect impact of COVID-19 on children and adolescents living with HIV across Europe and South Africa.

9

Jul, 2020

Paediatric HIV: we are not done yet!

Tags: HIV, AIDS, IAS

We met Martina Penazzato her and asked her thoughts on what urgent action we need to take to end AIDS in children.

6

Jul, 2020

Penta at the 23rd International AIDS Conference

Tags: HIV

The EPIICAL Project’s contribution to the 23rd International AIDS Conference

6

Jul, 2020

23rd International AIDS Conference

Tags: HIV

Central and Eastern European Meeting on Viral Hepatitis and HIV

Actual problems of HIV Infection: Mother and Child

The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus

A reason to SMILE – we reached Last Patient Last Visit

ODYSSEY trial data published in Lancet – shows increase in treatment options for older children living with HIV

The CARMA study: early infant antiretroviral therapy—Timing impacts on total HIV-1 DNA quantitation 12 years later

EPPICC focus on COVID-19 impact on children and adolescents living with HIV

Paediatric HIV: we are not done yet!

Penta at the 23rd International AIDS Conference

23rd International AIDS Conference

European research networks to facilitate drug research in children

Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets

The effect of pregnancy on the pharmacokinetics of total and unbound Dolutegravir and its main metabolite in women living with Human Immunodeficiency Virus

Clinically significant lower elvitegravir exposure during third trimester of pregnant patients living with HIV: data from the PANNA study